Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.

•First trial investigating pazopanib plus fosbretabulin in relapsed ovarian cancer.•The median PFS and OS favoured pazopanib plus fosbretabulin versus pazopanib alone.•Pazopanib plus fosbretabulin was associated with reversible cardiac toxicity.•The trial was discontinued due to cardiac toxicity in the experimental arm.